Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 6.6%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) shares were up 6.6% during mid-day trading on Monday . The stock traded as high as 1.69 and last traded at 1.69. Approximately 3,724,107 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 3,849,882 shares. The stock had previously closed at 1.58.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. B. Riley lifted their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a "buy" rating in a research note on Tuesday, April 9th. Oppenheimer reiterated an "outperform" rating and issued a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st.

Perspective Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07. The firm has a market capitalization of $962.55 million, a PE ratio of -16.40 and a beta of 1.56.

Insiders Place Their Bets

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business's stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company's stock, valued at approximately 110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.52% of the stock is owned by insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. ZWJ Investment Counsel Inc. purchased a new position in shares of Perspective Therapeutics during the 1st quarter valued at $26,000. Simplicity Wealth LLC purchased a new stake in shares of Perspective Therapeutics during the 1st quarter worth about $40,000. Bank of New York Mellon Corp acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at about $42,000. Taylor & Morgan Wealth Management LLC grew its stake in shares of Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company's stock valued at $251,000 after buying an additional 50,000 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in Perspective Therapeutics in the third quarter worth approximately $314,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.